Incidents
Georgia Poison Center GLP-1 Calls Climb From 38 to 655 as Gray-Market Dosing Errors Rise
By News Desk ·
Key takeaways
- Georgia Poison Center received 38 GLP-1 calls in 2021 and 655 so far in 2026, about a 1,600% increase.
- About one in five GLP-1 calls over the past two years involved unapproved drugs sold on the gray market, Dr. Gaylord Lopez said.
- About 15% of GLP-1 callers need emergency room evaluation, Lopez said.
- Eli Lilly's retatrutide is in Phase 3 trials and is not approved for public use.
Georgia Poison Center received 655 calls involving GLP-1 drugs so far in 2026, up from 38 in 2021, about a 1,600% increase, its executive director Dr. Gaylord Lopez said. Yahoo reported the figures on November 16, 2026.
The Georgia Poison Center is a department of Grady Health System and Georgia's only poison control center, according to akta.pro company records. It responds to more than 80,000 poison-related calls each year.
Inside the Georgia Poison Center Call Increase
Over the past two years, about one in five GLP-1 calls to the center involved unapproved drugs sold on what is often called the "gray market," Lopez said. About 15% of people who call about GLP-1 drugs end up needing evaluation in an emergency room.
"They're confusing milligrams with milliliters," Lopez said. "They may be using insulin syringes." He said unapproved products that consumers mix themselves carry infection risk because they are not prepared in sterile environments.
Hayley Lithwick, who said she had weighed over 300 pounds, began taking Zepbound, an FDA-approved prescription medication, after talking with a doctor. After a job change she lost insurance coverage for the drug and could no longer afford it.
Lithwick said she paid about $200 online for retatrutide, an investigational drug still in clinical trials. The website carried a warning that the product was "not for human or veterinary use, consumption, or application," and what arrived was powder in vials.
"I was very sketched out, but I kind of felt that there wasn't really a choice," Lithwick said. She mixed the powder herself using online instructions and later became sick with sweating, nausea and a fast heartbeat. She determined she had likely given herself about twice the intended dose.
"I was over 300 pounds before, and it really helped me a lot to lose a lot of weight and gain confidence," Lithwick said of GLP-1 medications. She said she has lost about 200 pounds overall.
Georgia Poison Center's Scale and Certification
According to company records, the Georgia Poison Center was founded in 1970 and is headquartered in Atlanta. It maintains American Association of Poison Control Centers certification as Georgia's only poison control center and submits data to the National Poison Data System. The center operates 24 hours a day, seven days a week, year-round, and provides toxicology rounding at five Atlanta-area metropolitan hospitals through Grady Health System.
Retatrutide's Phase 3 Status
Eli Lilly is developing retatrutide, the drug Lithwick said she purchased online. The drug is in Phase 3 clinical trials and is not currently approved for public use. The company has warned that retatrutide is not yet available for public use and that no one can legally sell the drug for human use while it remains an investigational medication.